These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19854838)

  • 1. Use of erythropoietins in patients with renal transplants.
    Treleaven DJ; Clase CM
    BMJ; 2009 Oct; 339():b3825. PubMed ID: 19854838
    [No Abstract]   [Full Text] [Related]  

  • 2. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 3. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study.
    Heinze G; Kainz A; Hörl WH; Oberbauer R
    BMJ; 2009 Oct; 339():b4018. PubMed ID: 19854839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The normal HCT trial re-revisited: what were the actual findings?
    Besarab A; Bolton WK; Nissenson AR; Schwab SJ
    Kidney Int; 2012 Jul; 82(2):242; author reply 242-3. PubMed ID: 22743566
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
    Vaziri ND; Zhou XJ
    Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic kidney disease anemia management: what should be done?
    Szczech LA
    Blood Purif; 2011; 31(1-3):186-8. PubMed ID: 21228588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full results on risks of epoetin emerge 14 years after major dialysis study.
    Epstein K
    BMJ; 2012 May; 344():e3535. PubMed ID: 22619221
    [No Abstract]   [Full Text] [Related]  

  • 9. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
    Winkelmayer WC
    J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
    [No Abstract]   [Full Text] [Related]  

  • 12. [Renal anemia treatment and outcome of patients with chronic kidney disease].
    Kuragano T; Nakanishi T
    Nihon Jinzo Gakkai Shi; 2009; 51(7):852-6. PubMed ID: 19928557
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA panel scrutinizes safety of anti-anemia drugs.
    Randal J
    J Natl Cancer Inst; 2004 Jul; 96(14):1061. PubMed ID: 15265966
    [No Abstract]   [Full Text] [Related]  

  • 14. New limits advised for anemia drugs.
    Mitka M
    JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
    [No Abstract]   [Full Text] [Related]  

  • 15. A physician's perseverance uncovers problems in a key nephrology study.
    Fishbane S; Wish JB
    Kidney Int; 2012 Jul; 82(2):135-7. PubMed ID: 22743565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
    Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
    J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amgen's point of view on epoetins.
    Seidenberg B; Perlmutter RM
    Lancet Oncol; 2004 Apr; 5(4):206-7. PubMed ID: 15050950
    [No Abstract]   [Full Text] [Related]  

  • 18. Anemia therapy in kidney disease. What research reveals about ESA medication safety.
    Johns Hopkins Med Lett Health After 50; 2010 Nov; 22(9):1-2, 7. PubMed ID: 21066834
    [No Abstract]   [Full Text] [Related]  

  • 19. An ongoing study of anemia correction in chronic kidney disease.
    Pfeffer MA;
    N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707
    [No Abstract]   [Full Text] [Related]  

  • 20. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.